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Abstract
Background: α-synucleinopathy emerges quite early in olfactory structures such as the olfactory bulb and
anterior olfactory nucleus (OB/AON) in Parkinson's disease. This may contribute to smell impairments years before
the commencement of motor symptoms. We tested whether α-synucleinopathy can spread from the OB/AON to
regions of the limbic telencephalon that harbor connections with olfactory structures.
Findings: α-synuclein fibrils were infused into the OB/AON. Inclusions containing pathologically phosphorylated
α-synuclein (pSer129) were observed three months later in the piriform and entorhinal cortices, amygdala, and
hippocampal formation. The retrograde tract-tracer FluoroGold confirmed the existence of first-order afferents at
these sites. Some sites harbored FluoroGold+ neurons but no inclusions, suggestive of selective vulnerabilities.
Multiple areas close to the injection site but not connected with the OB/AON remained free of inclusions, suggesting a
lack of widespread uptake of fibrils from interstitial diffusion. Two independent pSer129 antibodies revealed the same
labeling patterns and preadsorption control experiments confirmed a loss of pSer129 staining. Dense total α-synuclein
(but not pSer129) staining was apparent in the OB/AON 1.5 h following fibril infusions, suggesting that pSer129+ staining
did not reflect exogenously infused material. Waterbath sonication of fibrils for 1 h improved α-synucleinopathy
transmission relative to 1 min-long probe sonication. Electron microscopy revealed that longer sonication
durations reduced fibril size. The Thioflavin stain labeled cells at the infusion site and some, but not all inclusions
contained ubiquitin. Three-dimensional confocal analyses revealed that many inclusions ensconced NeuN+ neuronal
nuclei. Young and aged mice exhibited similar topographical spread of α-synucleinopathy.
Conclusions: 1) α-synucleinopathy in this model is transmitted through some, but not all neuroanatomical connections,
2) pathology is largely confined to first-order afferent sites at three months and this is most parsimoniously explained by
retrograde transport, and 3) transmission in aged animals is largely similar to that in young control animals at
three months post-infusion.
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Introduction
Due to the unique anatomical position of the olfactory
bulb (OB), this structure may be exposed to higher concen-
trations of inhaled environmental toxins and pathogens
than deeper brain structures. Perhaps as a result of these
exposures, olfactory dysfunction is an early feature of many
neurodegenerative conditions [1]. For example, approxi-
mately 90 % of Parkinson’s patients experience smell
disruption, which may affect their ability to detect decom-
posing food and hazardous fumes [2]. Some of the first
brain regions to develop α-synuclein+ Lewy pathology in
this condition are the OB and adjoining anterior olfactory
nucleus (AON), well before the emergence of Lewy
pathology in deeper mesencephalic structures [3–5]. α-
synucleinopathy has recently been speculated to spread
from cell to cell across neuroanatomical circuits, with
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the medulla oblongata as the potential “port of entry”
into the brain [3, 6–10]. Although α-synucleinopathy is
not thought to expand significantly into the brain from
olfactory structures compared to more extensive transmis-
sion from vagal/medullary nodes [3], if Lewy pathology
does spread through neuroanatomical circuits, its emer-
gence in olfactory areas such as the entorhinal allocortex
might serve as an important gateway into the hippocam-
pal archicortex. Lewy pathology in the hippocampus and
entorhinal cortex has profound implications for cognitive
dysfunction, which a sizeable fraction of patients with
Parkinson’s disease or Lewy body disease eventually de-
velop [11, 12]. Thus, the major goal of the present study
was to determine whether α-synucleinopathy could spread
from the OB/AON into limbic structures of the temporal
lobe in non-transgenic mice that do not overexpress
α-synuclein.
Rey and colleagues demonstrated that human α-
synuclein oligomers and monomers, but not fibrils, are
taken up following infusions into the OB and rapidly
transported to the AON and frontal and piriform corti-
ces within hours, but not to the entorhinal cortex or
hippocampus [13]. However, Lewy-like pathology was
not demonstrated in this short-term study. In an edifying
review article, Rey presented pilot data showing long-term
transmission of α-synucleinopathy from the OB into the
entorhinal cortex, amygdala, and hippocampal formation
[14]. However, the pathology was only shown at higher
magnification and appeared sparse, perhaps because the
α-synuclein injections were centered in the rostral extent
of the OB, distant from the AON [13, 14]. The AON is a
major site of olfactory pathology in Parkinson’s disease [3,
4, 15, 16]. Kordower and colleagues reported age-related
changes in α-synuclein expression that may influence the
development of Lewy pathology [17, 18]. Therefore, we
sought to develop a robust model of α-synucleinopathy in
the rhinencephalon of young and aged mice by infusing
preformed α-synuclein fibrils into the OB/AON.
Fibril sonication parameters are important in the trans-
mission of pathology [19]. Therefore, in the first study we
sonicated recombinant, wildtype α-synuclein fibrils of
mouse origin for 1 min with a probe or for 1 h in an inex-
pensive waterbath sonicator prior to infusion in the OB/
AON of two month-old mice. Three months later, sagittal
brain sections were collected and stained with a) the amyl-
oid stain Thioflavin S, b) two antibodies against patho-
logically phosphorylated α-synuclein (pSer129), and c) two
antibodies against ubiquitin—all established markers of
Lewy-like pathology [20–23]. A separate cohort of mice
was sacrificed 1.5 h following vehicle or fibril infusions to
visualize the center of the injection site, as this timepoint
shows the highest transfer of human α-synuclein following
OB injections according to Rey and colleagues [13]. In the
second study, we infused the retrograde tract-tracer
FluoroGold into the OB/AON in order to a) determine if
the sites that developed α-synucleinopathy in Study 1 pro-
ject directly into the OB/AON and b) again confirm the
center of the injection site at the stereotaxic coordinates
employed in the first study. As the first study revealed that
1 h waterbath sonication was more effective in eliciting
pathology than 1 min-long probe sonication, we per-
formed a third study with fibrils sonicated for 1 h or 24 h
in a waterbath. In order to confirm that the waterbath
sonication protocol would also work in a different set of
neuroanatomical circuits, we infused the CA2/CA3 fields
of the hippocampus in the third study. In previous studies
employing preformed α-synuclein fibrils, the fibrils were
also infused into the hippocampus, among other sites [6,
24]. CA2/CA3 were chosen as the target site of infusion
in the present study because they are the major hippo-
campal fields to exhibit α-synucleinopathy in Parkinson’s
disease or diffuse Lewy body disease [3, 25, 26]. Finally, in
order to ensure that the transmission of α-
synucleinopathy through the limbic rhinencephalon from
the OB/AON was reproducible, we performed a fourth
study infusing fibrils into the OB/AON of older animals (5
and 17 months of age). These experiments also allowed us
to determine if α-synucleinopathy transmission would be
more extensive with age-related loss of protein quality
control.
Methods
For sonication protocols, injection parameters, animal
numbers, statistics, etc., please see the detailed Methods
section in Additional file 1. All procedures were approved
by the Duquesne University IACUC (protocol 1403–03)
and in compliance with the NIH Guide. For the first study,
phosphate-buffered saline (PBS) or α-synuclein fibrils
(5 μg in 1 μL PBS; sonicated for 1 min with a probe or 1 h
in a waterbath) were unilaterally infused into the right
OB/AON of non-transgenic male CD1 mice at two
months of age. Sagittal brain sections were collected three
months later and stained with 1) Thioflavin S, 2) an anti-
body against the specific neuronal nuclear marker NeuN,
3) two antibodies against pSer129, and 4) two antibodies
against ubiquitin (see Additional file 1: Table S3). A separ-
ate cohort of animals was sacrificed 1.5 h post-infusion to
identify the center of the injection site and the extent of fi-
bril diffusion. For the second study, two month-old mice
were infused with the retrograde tracer FluoroGold into
the OB/AON to label afferent neurons that send direct
projections to the site of infusion and to again confirm the
center of the injection site at the same stereotaxic coordi-
nates as in the first study. For the third study, mice were
infused with PBS or fibrils (5 μg/1 μL; sonicated for 1 h or
24 h in a waterbath) into hippocampal CA2/CA3 and
sacrificed three months later, to ensure that the waterbath
sonication protocol worked in a different set of
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neuroanatomical circuits and to determine if 24 h sonic-
ation worked even better than 1 h sonication. For the
fourth study, older mice (5 and 17 months) were infused
with PBS or fibrils (5 μg/1 μL; 1 h waterbath-sonicated) into
the OB/AON to ensure reproducibility of α-
synucleinopathy transmission from olfactory structures and
to determine if there was spread to additional brain regions
in aged 17 month-old animals.
Results and discussion
Study 1: Transmission of α-synucleinopathy through the
limbic rhinencephalon from the OB/AON
Mice infused in the right OB/AON with fibrils sonicated
for 1 h in a waterbath displayed dense pSer129+ inclu-
sions in the olfactory peduncle (defined here as the
AON complex and the tenia tecta [27], Fig. 1, Additional
file 1: Table S2). Mice infused with fibrils sonicated for
1 min with a probe exhibited far less α-synucleinopathy
(Additional file 1: Table S2, Figure S1). PBS infusions did
not result in any α-synucleinopathy. pSer129+ inclusions
were formed in structures known to harbor anatomical
connections with the OB/AON, such as the amygdala,
the frontal, piriform, and entorhinal cortices, the nucleus
of the lateral olfactory tract, the subiculum, and hippocam-
pal CA1 [28–30] (Fig. 1a-c). Additional sparse pSer129
label was observed in some animals in CA2/CA3, the den-
tate gyrus, and the ectorhinal/perirhinal cortex (Additional
file 1: Table S2; Fig. 1a-b), perhaps reflecting limited transy-
naptic transport to these sites from CA1, the subiculum,
and the entorhinal cortex, all of which harbored dense in-
clusions (Fig. 1a-d) and project directly to the OB/AON
[28, 31, 32]. We invite the reader to download Fig. 1 in
high resolution and zoom in and out of the images in
Fig. 1b as with a street map, in order to appreciate the full
extent of the pSer129+ pathology and verify its anatomical
sublocalization. Note that the image takes an extremely
long time to fully populate the computer screen with high-
resolution photos, not only upon opening the file, but also
upon zooming in and navigating across brain regions. Most
α-synuclein-containing inclusions were wrapped around
Hoechst+ nuclei or found in processes (Fig. 1d). A blinded
analysis revealed that the number of pSer129+ structures in
the olfactory peduncle, the piriform and entorhinal corti-
ces, amygdala (posteromedial cortical amygdala), and hip-
pocampal formation (subiculum and CA1) were
dramatically higher in fibril-injected mice (Fig. 1e). The
SEM values in Fig. 1e reveal significant variability in hip-
pocampal and entorhinal inclusion counts, perhaps be-
cause of slight differences in stereotaxic placements of
infusate or inter-animal differences in vulnerability.
The most robust pathology was evident in the AON,
and this was far denser than in the OB itself (Add-
itional file 1: Figure S1, S2, Fig. 1a, cb, e, Additional file
1: Table S2), consistent with reports that the AON is
one of the main olfactory structures bearing Lewy path-
ology [3, 4, 15]. For AON subdivisions, please examine
the higher magnification images provided beneath Add-
itional file 1: Table S2 and the elegant work of Brunjes,
Haberly, and colleagues [27–30]. pSer129 labeling was
strikingly absent from the olfactory tubercle (Fig. 1a),
which receives dense first-order projections from the OB/
AON but does not send reciprocal projections back to ol-
factory structures [28–30], suggesting lack of anterograde
transmission of α-synucleinopathy.
The development of dense perinuclear and neuritic inclu-
sions following fibril infusions was confirmed with two in-
dependent (monoclonal and polyclonal) pSer129 antibodies
(see polyclonal anti-pSer129 staining in Fig. 1f, Additional
file 1: Figure S3). The staining with the polyclonal and
monoclonal antibodies overlapped well when applied sim-
ultaneously (Additional file 1: Figure S3). For preadsorption
controls for primary antibody specificity, we used the poly-
clonal pSer129 antibody because preadsorption controls
with monoclonal antibodies are always expected to lead to
loss of labeling regardless of which proteins they bind in tis-
sue [33]. Preincubation of pSer129 antibodies with pSer129
blocking peptide led to dramatic loss of immunoreactivity
relative to adjacent sections exposed to free, unbound pri-
mary antibodies (Fig. 1f). Omission of primary antibodies
also led to loss of immunofluorescent signal (not shown).
Next we characterized the nature of the inclusions
formed three months following fibril infusions into the
OB/AON. First, we confirmed that most perinuclear
pSer129+ inclusions were formed within cells expressing
the neuronal nuclear marker NeuN (Fig. 2a). This was
further verified by a confocal analysis (Fig. 2b) and then
by three-dimensional video analyses of the confocal im-
ages (see two videos in Additional file 2). The appearance
of the somal α-synuclein inclusions—fibrous perinuclear
strands—is similar to that reported in mouse tissue and
some human Lewy bodies by Osterberg and colleagues
[34]. Second, we examined whether the inclusions exhib-
ited characteristics of Lewy pathology. The Thioflavin S
stain for amyloid was applied to OB/AON tissue and
densely labeled cellular structures at the infusion site but
faintly or not at all elsewhere (Fig. 2c, Additional file 1:
Figure S4). Ubiquitin staining, a traditional method for de-
tecting Lewy-like pathology [22, 35], was present in some
but not all pSer129+ structures, as shown with two anti-
bodies against K48-linked ubiquitin (Fig. 2d, Additional
file 1: Figure S5). These findings are consistent with the
work of Osterberg et al. showing pSer129+ inclusions at
progressive stages of maturity, with mature inclusions
bearing hallmarks of Lewy pathology [34]. In addition, our
ubiquitin staining pattern is consistent with the classic
work of Spillantini et al. demonstrating that ubiquitin
only stains a portion of all α-synuclein+ Lewy bodies
and neurites [22].
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Previous work has shown that the fibrils themselves are
not phosphorylated [36]; the pSer129+ structures in the
present study therefore likely demark endogenous, aggre-
gated α-synuclein and not direct transport of injected
material as in the Rey study [13]. This interpretation is
consistent with the findings that 1) there was unexpectedly
sparse pSer129 labeling in the OB itself—the epicenter of
the fibril infusions—and 2) that there were no pSer129+
inclusions in animals sacrificed 1.5 h after fibril infusions
(Fig. 2e). However, the latter animals exhibited extremely
dense total (non-phosphorylated) α-synuclein immunore-
activity at the injection site relative to PBS-infused con-
trols, effectively delineating the center of the infusion site
in the caudal OB (Fig. 2e).
Study 2: Retrograde tract-tracing of first-order afferent
neurons that project to the site of infusion
The topography of the pSer129 label three months fol-
lowing fibril infusions into the OB/AON suggested that
brain regions projecting directly to the site of infusion
eventually developed inclusions. Thus, the retrograde
tracer FluoroGold was infused into the OB/AON at the
same stereotaxic coordinates in order to label first-order
afferent neurons that project directly to the injection site
(Fig. 3a). FluoroGold labeling of first-order projection
neurons was evident at all inclusion-bearing sites, with the
exception of the caudoputamen, accumbens, CA2/CA3,
and dentate gyrus (Additional file 1: Table S2). Further-
more, dense and brightly stained FluoroGold+ neurons
were additionally present in some areas not harboring any
pSer129+ pathology, such as the horizontal limb of the
diagonal band of Broca (Fig. 3aa, af-g, Additional file 1:
Table S2), which is known to project densely to the AON
[28–30] but resisted the development of α-synucleinopathy
(Fig. 1a, also see Fig. 4), suggestive of selective vulnerabil-
ities. No retrogradely labeled FluoroGold+ cells were
present in the olfactory tubercle (Fig. 3aa, af-g, Additional
file 1: Table S2), consistent with the lack of pSer129+ struc-
tures at this location (Fig. 1a, also see Fig. 4b, d, f) and with
previous reports that the olfactory tubercle does not pro-
ject to the OB/AON [28–30]. These findings suggest a lack
of anterograde transmission of α-synucleinopathy, as ar-
gued above, or additional selective vulnerabilities.
Study 3: Reproducibility of the fibril sonication protocol
in a separate set of neuroanatomical circuits
In order to confirm that our sonication protocol was re-
producible in a different set of neuroanatomical circuits,
we examined the spread of α-synucleinopathy through
the perforant path from CA2/CA3. These animals were
infused with vehicle or fibrils sonicated for 1 h or 24 h
in a waterbath, as 1 min-long probe sonication was less
successful in Study 1. Animals were sacrificed three
months later. Fibril infusions centered in CA2/CA3 of
the hippocampus led to dense pSer129+ inclusions at the
site of injection as well as CA1 and the dentate gyrus
(Fig. 3b-c). The entorhinal cortex was densely labeled in
fibril-infused animals, suggestive of successful α-synu-
cleinopathy transmission through the perforant path, as
in previous studies [24]. Additional pathology was
(See figure on previous page.)
Fig. 1 α-synucleinopathy is transmitted from the OB/AON to deeper rhinencephalic structures. Two month-old CD1 mice were unilaterally infused
with α-synuclein fibrils (5 μg) or an equal volume of phosphate-buffered saline (PBS) into the olfactory bulb and adjoining anterior olfactory nucleus
(OB/AON). Fibrils were sonicated for 1 h in a waterbath prior to infusion. Three months later, sagittal brain sections were collected and immunostained
for pathologically phosphorylated α-synuclein (pSer129; red). Fibril and PBS groups were stained and photographed in parallel. a Large, high-quality
microscopic photomontages of pSer129 and nuclear labeling were stitched together and viewed with Adobe Illustrator software on a tablet. Sagittal
schematics of only obvious and clearly visible brain cytoarchitectonics (solid lines), myelinated fiber bundles (gray shading), pSer129+ neurites (red
flourishes), and pSer129+ somal inclusions (red dots) were then traced with the pencil and paintbrush tools. All abbreviations are listed in
Additional file 1: Table S1. b Examples of stitched photomontages of pSer129 immunostaining and DRAQ5 nuclear labeling following fibril
infusions in the OB/AON (different sections than drawn in A). Please download the high-resolution supplemental versions of these files at the
link at the end of this article (Additional file 3) or email the corresponding author at leakr@duq.edu for access to the files and zoom in and out of the
stitched montages in order to appreciate the density of the pathology, distinguish it from background, and judge the precise anatomical location. c
pSer129 and nuclear Hoechst staining in the olfactory peduncle (a-b), the piriform cortex (c-d), and the hippocampus and amygdala (e-f) in PBS and
fibril-infused animals. Abbreviations in Additional file 1: Table S1. d Images of pSer129+ inclusions and Hoechst-stained nuclei were captured using a
100× oil objective. The pSer129+ inclusions were perinuclear or found in processes (also see confocal images in Fig. 2b and Additional file 2, which
shows two 3D-like videos of pSer129/NeuN labeled cells). The pSer129+ cell in the OB (uppermost row) was in the mitral cell layer, which is known to
house large somata. Images of the sparse label in the OB can be viewed in Additional file 1: Figure S1, S2, and the images below Additional file 1: Table
S2. e pSer129+ inclusion numbers were counted in ImageJ software by a blinded observer, after the same threshold values were applied across all im-
ages. Inclusion counts were 29.8 ± 20.2 (mean ± SEM) for PBS mice and 817.0 ± 242.5 for fibril mice in the olfactory peduncle; 17.2 ± 10.9 for PBS mice
and 154.6 ± 35.7 for fibril mice in the piriform cortex; 4.2 ± 2.2 for PBS mice and 140.8 ± 28.3 for fibril mice in the amygdala; 2.0 ± 0.9 for PBS mice and
102.6 ± 45.9 for fibril mice in the hippocampus; 27.4 ± 9.8 for PBS mice and 137.3 ± 50.7 for fibril mice in the entorhinal cortex; *p ≤ 0.05, **p ≤ 0.01, ***p ≤
0.001 vs PBS, Student’s t test (n= 4–5 mice/group). f Polyclonal antibodies against pSer129 were preadsorbed with pSer129 blocking peptide or incu-
bated alone for 24 h prior to application to tissue. Shown are adjacent sagittal sections from the same fibril-infused animal (1 h waterbath sonication),
captured with equivalent exposures and intensity scaling. Images showing the overlap between monoclonal and polyclonal pSer129 immunostaining
can be examined in Additional file 1: Figure S3. Additional preadsorption control data can also be viewed in Additional file 1: Figure S6
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evident in the ectorhinal/perirhinal region, which also
projects into the hippocampal formation [37] and has
been highlighted by Braak as an important node for the
spread of Lewy pathology from the mesocortex into the
neocortex in Braak stages 5 and 6 [3, 38]. Similar patterns
were observed with the polyclonal pSer129 antibody, and
this was again significantly reduced upon preadsorption
(Additional file 1: Figure S6). The antibody control experi-
ments—including colabeling with polyclonal and mono-
clonal antibodies—were performed on at least two
separate occasions, on coronal hippocampal tissue from
CA2/CA3 infusions and sagittal tissue from OB/AON in-
fusions, and the results were in agreement.
Hippocampal pathology was denser in the 1 h
waterbath-sonicated group relative to 24 h sonication
(Additional file 1: Figure S7), possibly because of over-
heating and degradation of α-synuclein over the course
of 24 h (the entire waterbath became hot). In order to
visualize fibril morphology under different sonication
conditions, we performed electron microscopy and ob-
served reductions in fibril size with 1 min probe sonic-
ation, 1 h waterbath sonication, and 24 h waterbath
sonication (Fig. 3d), as in previous work [39].
Study 4: α-synucleinopathy transmission from the OB/AON
of aged animals
In order to ensure that the transmission of α-
synucleinopathy from the OB/AON into deeper rhinen-
cephalic structures was reproducible, we injected a second
set of animals in the OB/AON with PBS or fibrils. Based
on the findings of the CA2/CA3 study (Study 3), the fibrils
were sonicated for 1 h. As an additional control, the inves-
tigator performing the stereotaxic surgeries was blinded to
the identity of the injected solutions. Animals were in-
fused at 5 or 17 months of age and sacrificed three
months later. The extent of pathology in older animals is
illustrated in Fig. 4. The pSer129 label in these fibril-
infused animals can be contrasted with the lack of inclu-
sions in large stitched montages of PBS-infused animals in
Additional file 1: Figure S8. These images from PBS mice
can also be deeply examined for background staining with
the pSer129 antibody. For the semi-quantitative analysis
shown in Additional file 1: Table S2, all the two month-
old animals from the first study were restained with
pSer129 antibodies in parallel with all the older animals in
order to control against inter-experimental variability in
immunofluorescence. The relative degree of staining in
each brain region was then rated by a blinded observer.
Relative to young animals, some aged (20 month old) ani-
mals exhibited more inclusions in the ventral striatum
(nucleus accumbens), which was not labeled retrogradely
with FluoroGold and therefore does not project to the
OB/AON injection site. These findings are consistent with
prior reports, as Rey and colleagues also reported striatal
and frontal cortical uptake of human α-synuclein follow-
ing OB infusions [13]. Two additional areas had sparse
and variable labeling in some animals and were not in-
cluded in the table, such as the bed nucIeus of stria
terminalis, which also projects to the OB/AON [40], and
the brainstem immediately caudal to the ventral portion
of the fasciculus retroflexus, in or near the parabrachial
nucleus. Both of these regions also harbored some Fluoro-
Gold+ cells.
Three important caveats of our study must be conceded.
First, rodents are macrosmatic animals (i.e., they depend
heavily upon olfaction) and therefore may exhibit denser
rhinencephalic interconnectivity than humans. It would
therefore be premature to conclude that hippocampal
Lewy pathology can be traced to the OB/AON in humans
based only on rodent work. Second, recent studies suggest
that labeling with the pSer129 antibody is subject to
cross-reaction with neurofilament-L [39]. Indeed, we
(See figure on previous page.)
Fig. 2 α-synucleinopathy is found within neuronal somata and some of it colocalizes with the ubiquitin marker of protein aggregates. a Two
month-old mice were unilaterally infused with α-synuclein fibrils (5 μg) or an equal volume of phosphate-buffered saline (PBS) into the olfactory
bulb and adjoining anterior olfactory nucleus (OB/AON). Fibrils were sonicated for 1 h in a waterbath prior to infusion. Three months later, sagittal
brain sections were collected and stained with antibodies against pSer129 and the neuronal nuclear marker NeuN. Hoechst-labeled nuclei are
shown in blue. Arrows point to some examples of the many triple-labeled cells in the AON. b Confocal microscopy showing the perinuclear
localization of pSer129+ structures in the AON. Arrows: examples of Hoechst+/NeuN+/pSer129+ profiles. Arrowhead: Hoechst+/NeuN−/pSer129+
profile. For three-dimensional movies of pSer129+ and NeuN+ cells, see Additional file 2. c Sagittal sections through the OB/AON were stained
with the Thioflavin amyloid stain. Nuclei were labeled blue with Hoechst. An additional sagittal level can be viewed in Additional file 1: Figure
S4. d Colocalization of ubiquitin, pSer129, and NeuN in five different brain regions in mice that were sacrificed 3 months after fibril infusions
in the OB/AON (1 h waterbath sonication). Some, but not all pSer129+ structures were ubiquitin+. The pSer129 and ubiquitin photos were
captured from fibril and PBS-treated animals at the same exposures and intensity scaling. To view the results of the second ubiquitin antibody,
please see Additional file 1: Figure S5. e Mice were infused in the OB/AON with 5 μg α-synuclein fibrils (1 h waterbath-sonicated) or PBS and
perfused 1.5 h later. Brain sections were stained with rabbit antibodies against phosphorylated or total α-synuclein (red). The needle track is
still apparent in the caudal OB at this early timepoint (white arrows) and reveals variability in the precise site of infusion, which would result in
differences in inclusion counts in those afferent neurons terminating in the OB/AON in highly topographical manners. Images from PBS
and fibril groups were captured at the same intensity scaling and exposure times. Differences in background staining are not the result of differential
image processing. For a high-resolution version of this figure, please download the image at the link at the end of this article (Additional file 3) or email
the corresponding author at leakr@duq.edu for access to the files
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see abundant evidence of background staining, espe-
cially in fiber tracts (see edges of olfactory peduncle in
Fig. 1ca-b, Additional file 1: Figure S1, photos below
Additional file 1: Table S2, polyclonal pSer129 staining in
Additional file 1: Figure S3a). To demonstrate that this
background staining did not confound our interpretations,
we have included enormous stitched montages of the
whole brain in fibril and PBS groups (Figs. 1b and 4, Add-
itional file 1: Figure S8). Although we cannot rule out all
cross-reactivity with certainty [24], the background label is
distinct from high-intensity labeling of inclusions, which
is absent in PBS animals, as is evident from the stitched
montages and the blinded quantification in Fig. 1e. It is
also worth mentioning that the antibody specificity con-
trols were successful (Fig. 1f, Additional file 1: Figure S3,
S6). The third limitation of the present study is that our
OB/AON model differs from the human condition in
many important ways—for example, OB/AON infusions
do not result in pathology in the olfactory tubercle or
dense hippocampal pathology in CA2/CA3. In Parkin-
son’s disease, α-synucleinopathy is hypothesized to
emerge first in enteric and olfactory structures and to
spread from the OB/AON regions to the olfactory tu-
bercle, piriform cortex, periamygdalear cortex, and en-
torhinal cortex (as observed in our study, with the
exception of the olfactory tubercle), but “without ad-
vancing into non-cortical areas” [41]. Instead, most α-
synucleinopathy is hypothesized to enter the human
brain from the dorsal motor nucleus of the vagus [3,
38]. It is worth noting, however, that most of the sites
exhibiting inclusions in Studies 1 and 4 are affected in
Braak stages 1–4 of Parkinson’s disease [3, 38]. Despite
the obvious differences between the models presented
here and the human condition, the fibril model may be
useful to test Heiko Braak’s hypotheses that neurons
with long, thin, unmyelinated axons, and perhaps high
metabolic rates, are more vulnerable to α-
synucleinopathy than neurons with sturdy, myelinated
axons [38, 42]. Such neurons may also exhibit impair-
ments in proteasomal and autophagic degradation
systems.
It is unlikely that diffusion and non-specific uptake of fi-
brils throughout all the interstitial space of the brain con-
founded our interpretations, as so many regions close to
the OB/AON remained free of inclusions (e.g., Fig. 4) and
the pSer129 label closely overlapped that of FluoroGold.
Had non-specific uptake following fibril diffusion through
the interstitial space been responsible for the pSer129
labeling, we would have expected a gradient of dense
labeling close to the injection site and sparse labeling with
increasing distance from the injection site, but this was
not the case; for example, in the OB/AON studies there
was dense label in distant locations such as the lateral and
caudal entorhinal cortex but absence of label in closer
sites such as the hypothalamus and thalamus (Studies 1
and 4). Similarly, in the CA2/CA3 study, the injection site
in the hippocampus lies close to many areas that were free
of pSer129 label (e.g., see thalamus and overlying cortex in
Fig. 3c, Additional file 1: Figure S7). Instead, the inclusion
topographies are most parsimoniously explained by pre-
ponderant transmission through anatomically linked cir-
cuits. Furthermore, the pSer129 antibodies are not simply
labeling the injected fibrils following diffusion, because
pSer129+ label was scarce at the OB infusion epicenter in
all fibril-treated animals and the inclusions were absent
1.5 h following fibril injections, a timepoint at which there
was a dramatic increase in total α-synuclein labeling in
the OB/AON relative to PBS controls.
(See figure on previous page.)
Fig. 3 Areas harboring α-synucleinopathy send first-order projections to the site of infusion in the OB/AON. a The retrograde tracer FluoroGold
(blue) was infused at the same stereotaxic coordinates as the α-synuclein fibrils. Animals were perfused after 7 days and sagittal sections were
stained with the nuclear marker DRAQ5 (purple). Sections were imaged under UV and CY5 illumination. Dual-stained brain regions appear red
(not purple or blue) in panel aa, such as the AON and the horizontal limb of the diagonal band (HDB). Dense FluoroGold label at multiple afferent
sites is illustrated at higher magnification in panels c, e, g, i, k, and m. Nuclear DRAQ5 label on the same sections is shown in panels b, d, f, h, j,
and l. Note the dense FluoroGold labeling in the horizontal limb of the diagonal band of Broca and the absence of FluoroGold label in the
olfactory tubercle (Tu; f-g). Neither of these regions developed α-synucleinopathy. The olfactory tubercle is densely innervated by OB/AON
projection neurons but does not project reciprocally back to the OB/AON. Abbreviations in Additional file 1: Table S1. b-c The transmission
of α-synucleinopathy after infusions of waterbath-sonicated fibrils can be generalized to other neuroanatomical circuits. Two month-old
mice were unilaterally infused with α-synuclein fibrils (5 μg) or an equal volume of phosphate-buffered saline (PBS) into CA2/CA3 of the hippocampus.
Fibrils were sonicated for 1 h in a waterbath prior to infusion. Three months later, coronal brain sections were collected. Shown are stitched montages
of pSer129 and Hoechst staining in the hippocampus and entorhinal cortex in PBS and fibril-infused animals—both groups were stained in parallel and
captured at the same exposure and intensity scaling. The fibril injection in this animal extended from CA2/CA3 into CA1. Note the dense label in the
entorhinal cortex, suggesting transmission of pathology through the perforant path, and the absence of label in the thalamus and most of the overlying
cortex, demonstrating the lack of nonspecific uptake by neighboring sites from diffusion through the cerebrospinal fluid and interstitial space. For the
antibody preadsorption control on coronal hippocampal tissue, see Additional file 1: Figure S6. To view the hippocampus at the same level after infusions
of fibrils that were sonicated for 24 h, please examine Additional file 1: Figure S7. Abbreviations in Additional file 1: Table S1. d Electron micrographs of
α-synuclein fibrils before and after sonication (1 min probe sonication and 1 h or 24 h waterbath sonication). Most sonicated fibrils were positively, not
negatively stained with uranyl acetate. To view the pSer129 pathology in the entorhinal cortex and transentorhinal region in panel c, please zoom in and
out of the high-resolution versions of these files at the link at the end of this article (Additional file 3) or email the corresponding author at leakr@duq.edu
for access to the files
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Fig. 4 α-synucleinopathy transmission from olfactory structures in older mice. Mice (17 months old) were unilaterally infused in the OB/AON with
α-synuclein fibrils (1 h waterbath sonication; see study on older animals in main text and in Additional file 1). Three months later, sagittal brain
sections were collected and stained for DRAQ5 (a, c, e, g, i) and pSer129 (b, d, f, h, j). In order to fully appreciate the density of the inclusions and
the neuroanatomical sublocalization, the reader must zoom in and out of the stitched pSer129 montages in the high-resolution versions of these files
at the link at the end of this article (Additional file 3) or email the corresponding author at leakr@duq.edu for access to the files and examine panels
k-m. The extent and density of the label in these fibril-infused animals should be contrasted with the lack of inclusions in large stitched montages of
PBS-infused animals in Additional file 1: Figure S8. Abbreviations in Additional file 1: Table S1. k-m Higher magnification views of PBS versus fibril-
infused cases. Shown are the olfactory peduncle (k), the hippocampus (l), and the piriform cortex (m). The entire brain section of these PBS cases can
be fully examined for background staining in Additional file 1: Figure S8. The scale bar for a-j is in panel A and the scale bar for k-m is in panel m
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In conclusion, the present short report demonstrates
that 1) α-synucleinopathy can spread from the rostrally
and medially situated OB/AON all the way to the caudal
recesses of the temporal lobe (hippocampal formation and
entorhinal cortex) within three months, 2) the spread of
pathology is consistent with retrograde transmission
through neuroanatomical networks, although this obvi-
ously remains to be confirmed, 3) some first-order afferent
sites retrogradely transport FluoroGold from the OB/
AON but resist the development of α-synucleinopathy,
and 4) age at fibril infusion does not make a robust differ-
ence in α-synucleinopathy transmission in the first three
months. Although our findings are consistent with the
olfactory vector hypothesis of Parkinson’s disease [2] and
may be especially relevant to diffuse Lewy body disease or
dementia with Lewy bodies, it is difficult to extrapolate
from rodent data directly to humans. If such extrapolation
is eventually validated, then our findings may have im-
plications for neurological outcomes, such as those
controlled by the piriform and entorhinal cortices,
amygdala, hippocampus proper, and subiculum. For ex-
ample, memory loss in Parkinson’s disease is associated
with α-synuclein pathology in CA2, the amygdaloid
complex, and the entorhinal cortex and with tissue at-
rophy in CA1, CA3, and the subiculum [43, 44]. Indeed,
loss of olfaction is a harbinger of cognitive dysfunction
and memory loss [45–47] and predicts mortality in se-
nior citizens; 22 % to 40 % of older adults with anosmia
are dead within 5 years, as opposed to 10 % of elderly
subjects with intact olfaction [48, 49].
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